Needham & Company LLC Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $202.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price target decreased by Needham & Company LLC from $205.00 to $202.00 in a report published on Wednesday, Marketbeat Ratings reports. Needham & Company LLC currently has a buy rating on the biotechnology company’s stock.

Other analysts have also issued research reports about the stock. Guggenheim increased their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. HC Wainwright assumed coverage on Sarepta Therapeutics in a report on Monday, November 25th. They issued a “sell” rating and a $80.00 target price on the stock. UBS Group boosted their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Raymond James reaffirmed an “outperform” rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Finally, Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $175.77.

Sarepta Therapeutics Trading Down 3.3 %

SRPT opened at $133.34 on Wednesday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a twelve month low of $78.67 and a twelve month high of $173.25. The stock has a market capitalization of $12.74 billion, a price-to-earnings ratio of 106.67 and a beta of 0.81. The company has a 50-day simple moving average of $122.50 and a 200 day simple moving average of $131.49.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds have recently made changes to their positions in SRPT. Innealta Capital LLC bought a new position in Sarepta Therapeutics during the second quarter worth $31,000. New Covenant Trust Company N.A. bought a new position in shares of Sarepta Therapeutics in the 1st quarter worth about $32,000. Sunbelt Securities Inc. lifted its stake in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank boosted its position in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. Finally, Nkcfo LLC acquired a new stake in Sarepta Therapeutics during the second quarter worth approximately $43,000. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.